<DOC>
	<DOCNO>NCT00287534</DOCNO>
	<brief_summary>The purpose study determine efficacy tolerability 3 year treatment anastrozole prior 2 year ' treatment tamoxifen versus 5 year treatment tamoxifen postmenopausal woman early breast cancer</brief_summary>
	<brief_title>Effectiveness Combination Arimidex Nolvadex Adjuvant Therapy Breast Carcinoma Postmenopausal Women .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Signed informed consent , Postmenopausal woman â‰¤75 year , histologically confirm invasive breast carcinoma ( distant metastasis ) , positive hormone receptor status , continuous 2year adjuvant tamoxifen therapy 20 mg/30 mg 4 week primary surgery menopause status maintain medication , preoperative chemotherapy hormone therapy radiation therapy , relapse second carcinoma previous cancerous disease , breast carcinoma situ , simultaneous carcinoma opposite side secondary breast , 10 tumourinfiltrated lymph node . serious accompany disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Early Breast Cancer</keyword>
</DOC>